Orthodenticle Homeobox OTX1 is a Potential Prognostic Biomarker for Bladder Cancer

Overview

Journal Bioengineered

Date 2021 Sep 24

PMID 34559577

Citations 11

Authors

Lei Jiang

Zhongqiang Zuo

Jie Lin

Chuanfeng Yang

Affiliations

Soon will be listed here.

Abstract

Bladder cancer (BC) is one of the most aggressive tumors worldwide. OTX1 (orthodenticle homeobox 1) is an important transcription factor involved in various diseases, such as cancers. The aim of this study was to further investigate the role of OTX1 in BC. In this study, differentially expressed genes (DEGs) were screened from tumor tissues and para-cancerous tissues by bioinformatics. The expression of protein and RNA was separately detected by western blotting and immunohistochemistry (IHC), and quantitative polymerase chain reaction (qPCR); cell viability and cell growth were determined by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and clone formation assays, respectively; cell motility was measured by transwell and wound healing assays; cell cycle was measured by flow cytometry. In this study, 9 DEGs were screened out, and OTX1 was employed as a candidate gene for subsequent study. Results found that OTX1 was highly expressed in BC cells and BC tissues, which was significantly associated with poor prognosis of patients. In addition, OTX1 silencing significantly reduced cell viability, and inhibited cell growth and motility, while OTX1 overexpression got opposite results. Moreover, OTX1 co-expressed genes were enriched in cell cycle-related pathways, suggesting that the role of OTX1 in BC may be related to cell cycle, which was confirmed by flow cytometry analysis. Furthermore, experiments showed that OTX1 silencing significantly inhibited tumor growth in tumor-bearing mice. Taken together, our findings suggested that OTX1 may play a promotional role in BC progression.

Citing Articles

The Relationship of the Pathogenic Variant rs721048 in the Intron of the Gene with the Development of Prostate Cancer and Colorectal Cancer in the Kazakh Population.

Romanova M, Abdikerim S, Dauyey K, Gassanov Z, Baltayev N, Satymbayev S Genes (Basel). 2025; 16(2).

PMID: 40004500 PMC: 11855340. DOI: 10.3390/genes16020171.

A Molecular Urine Assay to Detect Recurrences During Surveillance of High-Risk Non-Muscle Invasive Bladder Cancer.

de Jong J, de Jong F, van der Made A, van Casteren N, Roshani H, Oomens E Bladder Cancer. 2024; 10(3):233-242.

PMID: 39493819 PMC: 11530022. DOI: 10.3233/BLC-240017.

Hypermethylation Loci of ZNF671, IRF8, and OTX1 as Potential Urine-Based Predictive Biomarkers for Bladder Cancer.

Jiang Y, Liu Y, Wei Y, Jhang J, Kuo H, Huang H Diagnostics (Basel). 2024; 14(5).

PMID: 38472940 PMC: 10931331. DOI: 10.3390/diagnostics14050468.

Genes in Adult Tissues.

Terrinoni A, Micheloni G, Moretti V, Caporali S, Bernardini S, Minieri M Int J Mol Sci. 2023; 24(23).

PMID: 38069286 PMC: 10707059. DOI: 10.3390/ijms242316962.

Orthodenticle Homeobox OTX1 Promotes Papillary Thyroid Carcinoma Progression and Is a Potential Prognostic Biomarker.

Wei J, Wang X, Jiao K Genet Res (Camb). 2023; 2023:5513812.

PMID: 37780815 PMC: 10539079. DOI: 10.1155/2023/5513812.

References

Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L . Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2006; 66(6 Suppl 1):4-34. DOI: 10.1016/j.urology.2005.07.062. View

Cui Z, Liu Y, Zhang J, Qiu X . Super-delta2: an enhanced differential expression analysis procedure for multi-group comparisons of RNA-seq data. Bioinformatics. 2021; 37(17):2627-2636. DOI: 10.1093/bioinformatics/btab155. View

Ling B, Liao X, Huang Y, Liang L, Jiang Y, Pang Y . Identification of prognostic markers of lung cancer through bioinformatics analysis and in vitro experiments. Int J Oncol. 2019; 56(1):193-205. PMC: 6910184. DOI: 10.3892/ijo.2019.4926. View

Meijuan W, Mao X, Wang S . Clinical significance of miR-139-5p and FGF2 in ovarian cancer. J BUON. 2021; 26(3):663-669. View

Lopez-Beltran A, Cimadamore A, Blanca A, Massari F, Vau N, Scarpelli M . Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. Cancers (Basel). 2021; 13(1). PMC: 7795541. DOI: 10.3390/cancers13010131. View

Li H, Miao Q, Xu C, Huang J, Zhou Y, Wu M . OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway. J Korean Med Sci. 2016; 31(8):1215-23. PMC: 4951550. DOI: 10.3346/jkms.2016.31.8.1215. View

Mati Q, Qamar S, Ashraf S, Khokhar M, Arshad U . Tissue Nuclear Matrix Protein Expression 22 in Various Grades and Stages of Bladder Cancer. J Coll Physicians Surg Pak. 2021; 30(12):1321-1325. DOI: 10.29271/jcpsp.2020.12.1321. View

Qin S, Zhao Z, Sheng J, Xu X, Yao J, Lu J . Dowregulation of OTX1 attenuates gastric cancer cell proliferation, migration and invasion. Oncol Rep. 2018; 40(4):1907-1916. PMC: 6111461. DOI: 10.3892/or.2018.6596. View

Smyth G, Speed T . Normalization of cDNA microarray data. Methods. 2003; 31(4):265-73. DOI: 10.1016/s1046-2023(03)00155-5. View

10.

Yang C, Wang L, Mu D, Li F, Ran P, Shen H . OTX1 is a novel regulator of proliferation, migration, invasion and apoptosis in lung adenocarcinoma. Eur Rev Med Pharmacol Sci. 2020; 24(18):9497-9510. DOI: 10.26355/eurrev_202009_23035. View

11.

Skopinska-Rozewska E, Janik P, Przybyszewska M, Sommer E, Bialas-Chromiec B . Inhibitory effect of theobromine on induction of angiogenesis and VEGF mRNA expression in v-raf transfectants of human urothelial cells HCV-29. Int J Mol Med. 1998; 2(6):649-52. DOI: 10.3892/ijmm.2.6.649. View

12.

Mounir M, Lucchetta M, C Silva T, Olsen C, Bontempi G, Chen X . New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx. PLoS Comput Biol. 2019; 15(3):e1006701. PMC: 6420023. DOI: 10.1371/journal.pcbi.1006701. View

13.

Yu K, Cai X, Li Q, Yang Z, Xiong W, Shen T . OTX1 promotes colorectal cancer progression through epithelial-mesenchymal transition. Biochem Biophys Res Commun. 2014; 444(1):1-5. DOI: 10.1016/j.bbrc.2013.12.125. View

14.

Tu X, Li H, Chen L, Luo X, Lu Z, Zhang S . OTX1 exerts an oncogenic role and is negatively regulated by miR129-5p in laryngeal squamous cell carcinoma. BMC Cancer. 2020; 20(1):794. PMC: 7446126. DOI: 10.1186/s12885-020-07279-1. View

15.

Ludlow A, Wong M, Robin J, Batten K, Yuan L, Lai T . NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer. Nat Commun. 2018; 9(1):3112. PMC: 6079032. DOI: 10.1038/s41467-018-05582-x. View

16.

de Haas T, Oussoren E, Grajkowska W, Perek-Polnik M, Popovic M, Zadravec-Zaletel L . OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas. J Neuropathol Exp Neurol. 2006; 65(2):176-86. DOI: 10.1097/01.jnen.0000199576.70923.8a. View

17.

Wada S, Sudou N, Saiga H . Roles of Hroth, the ascidian otx gene, in the differentiation of the brain (sensory vesicle) and anterior trunk epidermis in the larval development of Halocynthia roretzi. Mech Dev. 2004; 121(5):463-74. DOI: 10.1016/j.mod.2004.03.017. View

18.

Ponten F, Gry M, Fagerberg L, Lundberg E, Asplund A, Berglund L . A global view of protein expression in human cells, tissues, and organs. Mol Syst Biol. 2009; 5:337. PMC: 2824494. DOI: 10.1038/msb.2009.93. View

19.

Shi S, Tian B . Identification of biomarkers associated with progression and prognosis in bladder cancer via co-expression analysis. Cancer Biomark. 2019; 24(2):183-193. DOI: 10.3233/CBM-181940. View

20.

Omodei D, Acampora D, Russo F, De Filippi R, Severino V, di Francia R . Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B cells and in aggressive Non-Hodgkin Lymphoma. Am J Pathol. 2009; 175(6):2609-17. PMC: 2789631. DOI: 10.2353/ajpath.2009.090542. View